Overview

Paediatric Ards Neuromuscular Blockade Study

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Paediatric acute respiratory distress syndrome (ARDS) is a manifestation of severe, life-threatening lung injury. Care for paediatric patient is mainly supportive and based on what works in adults and personal experiences, including the use of mechanical ventilation. However, differences in lung physiology and immunology between (young) children and adults suggests that adaptation of adult practices into paediatrics may not be justified. A study in adults with severe ARDS showed that early use of neuromuscular blocking agents (NMBA) improved 90-day survival and increased time off the ventilator without increasing muscle weakness. It is unknown if this is also true for paediatric ARDS
Phase:
Phase 4
Details
Lead Sponsor:
University Medical Center Groningen
Treatments:
Neuromuscular Blocking Agents
Rocuronium